Cantor Fitzgerald analyst Charles Duncan downgraded Jazz Pharmaceuticals (JAZZ) to Neutral from Overweight with a price target of $150, up from $140.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $205 from $195 at TD Cowen
- Jazz Pharmaceuticals: Strong Buy Rating Backed by Robust Financial Performance and Strategic Growth Initiatives
- Jazz Pharmaceuticals price target raised to $167 from $162 at Baird
- Positive Outlook for Jazz Pharmaceuticals: Strategic Wins and Promising Financial Projections Lead to Buy Rating
- Jazz Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating